Work

Efficacy of first line (1L) poly ADP-ribose polymerase inhibitors (PARPi) in combination with androgen pathway inhibitors (API) by homologous recombination repair (HRR) genes in metastatic castration-resistant prostate cancer (mCRPC): A living meta-analysis.

Year: 2024

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2024.42.16_suppl.e17059

Authors: Arifa Bibi, Syed Arsalan Ahmed Naqvi, Muhammad Ali Khan, Ammad Raina, Kaneez Zahra Rubab Khakwani, Jacob Orme, Daniel S Childs, Adam McLain Kase, Sylvan C. Baca, Oliver Sartor, Parminder Singh, Alan Haruo Bryce, Irbaz Bin Riaz

Institutions: Mayo Clinic, Mayo Clinic Hospital, Canandaigua VA Medical Center, University of Arizona, Mayo Clinic in Florida, Mayo Clinic in Arizona

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4399394498

Cites:

Cited by: 1

Related to: 10